165 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF S6: RESULTS OF RISK OF BIAS ASSESSMENT. Selection Comparability Outcome Missing data Author Year Reference Representativeness of the exposed cohort Selection of the non-exposed cohort Ascertainment of exposure Demonstration that outcome of interest was not present at start of study Comparability of cohorts on the basis of the design or analysis Assessment of outcome Was follow-up long enough for outcomes to occur Adequacy of follow-up of cohorts Handling missing data Arbel 2019 114 * * * ** * * Atarashi 2021 115 * * * ** * * Briasoulis 2020 116 * * ** * * Cho 2020 117 * * ** * * de Groot 2020 118 * * * * * Ikeda 2019 119 * * * ** * * Inoue 2019 120 * * * * * * * Inoue 2020 121 * * * * * * Kobayashi 2020 122 * * * ** * * * Lee 2017 123 * * * ** * * Lee 2019 124 * * * ** * * Lee 2021 125 * * * ** * * Murata 2019 126 * * * ** * * * Ohno 2020 127 * * * ** * * * Salameh 2020 128 * * * ** * * Steinberg 2018 129 * * * ** * * * * Tellor 2017 130 * * * * Yagi 2019 131 * * * * * Yao 2017 132 * * * ** * * 8
RkJQdWJsaXNoZXIy MTk4NDMw